Compare CLGN & WVVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CLGN | WVVI |
|---|---|---|
| Founded | 2004 | 1983 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Beverages (Production/Distribution) |
| Sector | Health Care | Consumer Staples |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 33.8M | 13.0M |
| IPO Year | N/A | N/A |
| Metric | CLGN | WVVI |
|---|---|---|
| Price | $1.82 | $2.84 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $11.50 | N/A |
| AVG Volume (30 Days) | ★ 20.8K | 7.3K |
| Earning Date | 11-26-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $2,475,000.00 | ★ $37,366,837.00 |
| Revenue This Year | $1,617.28 | N/A |
| Revenue Next Year | $83.54 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 280.77 | N/A |
| 52 Week Low | $1.31 | $2.49 |
| 52 Week High | $4.98 | $7.18 |
| Indicator | CLGN | WVVI |
|---|---|---|
| Relative Strength Index (RSI) | 36.52 | 51.14 |
| Support Level | $1.77 | $2.71 |
| Resistance Level | $1.93 | $3.00 |
| Average True Range (ATR) | 0.15 | 0.16 |
| MACD | -0.03 | 0.06 |
| Stochastic Oscillator | 10.20 | 87.23 |
CollPlant Biotechnologies Ltd is a regenerative and aesthetic medicine company focused on 3D bioprinting of tissues and organs and medical aesthetics. Its products are based on its rhCollagen (recombinant human collagen) produced with CollPlant's proprietary plant based genetic engineering technology. These products address indications for the diverse fields of tissue repair, aesthetics, and organ manufacturing. The revenues include income from business collaborators and sales of the BioInk product for the development of 3D bioprinting of organs and tissues, sales of rhCollagen for the medical aesthetics market, and sales in Europe of the products for tendinopathy and wound healing. The company operates in United States, which derives key revenue, Canada, Europe and Other, and Israel.
Willamette Valley Vineyards Inc produces and sells premium, super-premium, and ultra-premium wines. The grapes are harvested, fermented, and made into wine at the company's Turner winery, and the wines are sold principally under its Willamette Valley Vineyards label and also under the Griffin Creek, Tualatin Estate, Pambrun, Maison Bleue, Natoma, Metis, and Elton labels. It operates under two operating segments, direct sales and distributor sales. Direct sales include retail sales in its tasting room and remote sites, wine club sales, online sales, on-site events, kitchen and catering sales, and other sales made directly to the consumer without the use of an intermediary. Distributor sales include all sales through a third party where prices are given at a wholesale rate.